Abstract
Purpose
Fentanyl is a synthetic opioid available therapeutically as an intravenous, transbucal, or transdermal preparation. It is also used as a drug of abuse through a variety of different methods, including the oral abuse of transdermal fentanyl patches. This is a series of patients with oral fentanyl patch exposure reported to our center and represents the first series of oral fentanyl patch exposures collected outside of the postmortem setting.
Methods
In this series, we examined the New York Poison Control Center database for all cases of oral abuse of fentanyl reported between January 2000 and April 2008.
Results
Twenty cases were reported, nine were asymptomatic or had symptoms of opioid withdrawal; 11 had symptoms of opioid intoxication. Eight patients were administered naloxone and all showed improvement in clinical status. Only one case resulted in a confirmed fatality—this patient had an orally adherent patch discovered at intubation.
Conclusions
Oral exposure may result in life-threatening toxicity. Patients should be closely assessed and monitored for the opioid toxidrome, and if symptomatic, should be managed with opioid antagonists and ventilatory support.
Keywords: Fentanyl, Transdermal fentanyl, Opioid, Oral abuse
Full Text
The Full Text of this article is available as a PDF (106.3 KB).
Contributor Information
Jane M. Prosser, Email: jprosser100@gmail.com
Brent E. Jones, Phone: +1-540-7721512, FAX: +1-540-2667596, Email: brent.e.jones@gmail.com
References
- 1.Mather LE. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet. 1983;8:422–446. doi: 10.2165/00003088-198308050-00004. [DOI] [PubMed] [Google Scholar]
- 2.Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the food and drug administration, 1998–2005. Arch Intern Med. 2007;167:1752–1758. doi: 10.1001/archinte.167.16.1752. [DOI] [PubMed] [Google Scholar]
- 3.Nelson LS (2006) Opioids. In: Goldfrank’s Toxicologic Emergencies. 8th (ed.) New York: McGraw-Hill, pp 540–613
- 4.http://drugtopics.modernmedicine.com/Pharmacy+Facts+&+Figures. Last accessed 03/28/08.
- 5.Nelson LS, Schwaner R. Transdermal fentanyl: pharmacology and toxicology. J Med Toxicol. 2009;5:230–241. doi: 10.1007/BF03178274. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Janssen Pharmaceutical. Duragesic®approved package insert. Titusville, NJ. Available from: http://www.duragesic.com/duragesic/shared/pi/duragesic.pdf. Last accessed 06/06/2009.
- 7.Anderson DT, Muto JJ. Duragesic transdermal patch: postmortem tissue distribution of fentanyl in 25 cases. J Anal Toxicol. 2000;24:627–634. doi: 10.1093/jat/24.7.627. [DOI] [PubMed] [Google Scholar]
- 8.Coon TP, Miller M, Kaylor D, Jones-Spangle K. Rectal Insertion of fentanyl patches: a new route of toxicity. Ann Emerg Med. 2005;45:473. doi: 10.1016/j.annemergmed.2005.06.450. [DOI] [PubMed] [Google Scholar]
- 9.Tharp AM, Winecker RE, Winston DC. Fatal intravenous fentanyl abuse: four cases involving extraction of fentanyl from transdermal patches. Am J Forensic Med Pathol. 2004;25:178–181. doi: 10.1097/01.paf.0000127398.67081.11. [DOI] [PubMed] [Google Scholar]
- 10.Marquardt KA, Tharratt RS. Inhalation abuse of fentanyl patch. Clin Toxicol. 1994;32:75–78. doi: 10.3109/15563659409000433. [DOI] [PubMed] [Google Scholar]
- 11.Streisand JB, Varvel JR, Stanski DR, et al. Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology. 1991;75:223–229. doi: 10.1097/00000542-199108000-00009. [DOI] [PubMed] [Google Scholar]
- 12.Jentzen JM. Alternative drug-delivery systems are subject to abuse. In: Clinical and Forensic Toxicology News. http://www.aacc.org/publications/toxicology/Documents/9023f590e32540b29c02cf27a1320efedec03.pdf. Last accessed 09/01/2009.
- 13.Barrueto F, Jr, Howland MA, Hoffman RS. The fentanyl tea bag. Vet Human Toxicol. 2004;46:30–31. [PubMed] [Google Scholar]
- 14.http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm163647.htm. Last accessed 10/20/2009.
- 15.http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm172039.htm. Last accessed 10/20/2009.
- 16.Varvel JR, Shafer SL, Hwang SS, et al. Absorbtion characteristics of transdermally administered fentanyl. Anesthesiology. 1989;70:928–934. doi: 10.1097/00000542-198906000-00008. [DOI] [PubMed] [Google Scholar]
- 17.Arroyo AM, Smith J, Kriger S, Mowry J. In-vitro release of fentanyl from transdermal patches in gastric and intestinal fluid. Clin Toxicol. 2009;47:706. doi: 10.3109/15563650.2014.967399. [DOI] [PubMed] [Google Scholar]
- 18.Hardwick WE, King WD, Palmisano PA. Respiratory depression in a child unintentionally exposed to transdermal fentanyl patch. South Med J. 1997;90:962–964. doi: 10.1097/00007611-199709000-00023. [DOI] [PubMed] [Google Scholar]
- 19.Marquardt KA, Tharratt RS, Musallam NA. Fentanyl remaining in a transdermal system following three days of continuous use. Ann Pharmacother. 1995;29:969–971. doi: 10.1177/106002809502901001. [DOI] [PubMed] [Google Scholar]
- 20.Woodall KL, Martin TL, McLellan BA. Oral abuse of fentanyl patches (Duragesic): seven case reports. J Forensic Sci. 2008;53:222–225. doi: 10.1111/j.1556-4029.2007.00597.x. [DOI] [PubMed] [Google Scholar]
- 21.Kuhlman JJ, McCaulley R, Valouch TJ, Behonick GS. Fentanyl use, misuse, and abuse: a summary of 23 postmortem cases. J Anal Toxicol. 2003;27:499–504. doi: 10.1093/jat/27.7.499. [DOI] [PubMed] [Google Scholar]
- 22.Kramer C, Tawney M. A fatal overdose of transdermally administered fentanyl. J Am Osteo Assoc. 1998;98:385. [PubMed] [Google Scholar]
- 23.Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet. 2000;38:59–89. doi: 10.2165/00003088-200038010-00004. [DOI] [PubMed] [Google Scholar]
- 24.Howland MA (2006) Antidotes in depth: naloxone. In Goldfrank’s Toxicologic Emergencies 8th (ed.) New York: McGraw-Hill. pp 540–613